Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Anti-HER2 scFv-Fc(Ser396Sec)/CN29 is a novel selenomab drug conjugate with activity in vivo

April 3, 2017

HMBD-001, a novel anti-ERBB3 antibody that inhibits tumor growth in preclinical models

April 3, 2017

FDA advisory committee recommends approval of subcutaneous rituximab

March 31, 2017

iDD biotech signs license agreement for antibodies targeting CK8

March 31, 2017

FDA grants priority review to Blincyto sBLA

March 30, 2017

Hanmi Pharmaceutical and Innovent Biologics establish immuno-oncology partnership

March 30, 2017

Interim data from phase Ib study of DPX-Survivac with epacadostat in ovarian cancer

March 30, 2017

FDA grants priority review to BLA filing for CTL-019 for relapsed or refractory B-cell ALL

March 30, 2017

S3F-CL-MMAE as a novel anti-STn ADC with promising antitumor activity in vivo

March 30, 2017

Compugen selects COM-902 as immuno-oncology antibody candidate

March 30, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.